drugset / Trial / NCT05601219
A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study consists of dose escalation evaluation to determine the safety and tolerability of ADA-011 as a monotherapy. Following dose escalation, one or more dose expansion cohorts in selected indications will be explored to further evaluate the safety, tolerability, and preliminary efficacy of ADA-011.
Timeline
- Start
- 2022-11-15
- Primary completion
- 2024-10-30
- Completion
- 2024-10-30
Outcome
Outcome not reported
Stopped: “Internal company decision (non-safety related)”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ADA-011 | Monoclonal antibody | — | Intravenous |